NYSEHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading EVH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround situation with low confidence in earnings quality and elevated risk. The current thesis state is cautious, as recent performance has been weak and the company is loss-making.
The market seems to have priced in a justified valuation that is cheap compared to peers. There is an expectations gap indicating that the market anticipates continued challenges ahead.
Management is on track to achieve its 2026 revenue guidance, but the adjusted EBITDA guidance remains mixed. The near-term risk is relatively low, though the company has a history of missing expectations.
The thesis hinges on the performance of sector bellwethers like VEEV, BTSG, and TEM. If these companies continue to perform well, it could provide a favorable backdrop for EVH. Conversely, any negative guidance from these peers could lead to further challenges for EVH.
Overall, the next 1 to 3 years will be critical for EVH as it navigates a mixed performance landscape. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. There are no new strengths or weaknesses identified. Recent financial performance remains weak compared to its industry peers. Management is still behind on a stated commitment.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will give insights into revenue and profit trends.
Confirms one read:Earnings report shows revenue and EBITDA in line with or exceeding guidance.
Confirms the other:The earnings report shows big misses on revenue or EBITDA, which raises concerns.
Why it matters: Meeting this target supports the company's goal of reaching $2.4B to $2.6B in 2026 revenue.
Confirms:Q2 revenue reported at or above $600 million.
Disproves:Q2 revenue falls below $580 million.
Why it matters: Keeping this guidance shows the company can control costs while growing. It affects how investors see profitability.
Confirms one read:Adjusted EBITDA was between $110M and $140M. This confirms management's outlook.
Confirms the other:Adjusted EBITDA was below $110M. This shows possible cost problems or lower profits.
Why it matters: Faster sector growth could help Evolent perform better.
Confirms:Health Care sector revenue growth shows signs of re-accelerating back toward highs.
Disproves:Sector growth keeps slowing down, affecting Evolent's outlook.
Why it matters: Spending at this level shows commitment to technology and growth. It can enhance future revenue potential.
Confirms:Capitalized software spending was $25M or more. This shows strong investment in technology.
Disproves:Capitalized software spending was below $25M. This suggests less investment in growth.
Why it matters: The earnings miss could affect investor confidence and future growth outlook.
Confirms:Q2 results show a recovery from the earnings miss with improved metrics.
Disproves:Q2 results reflect continued weakness after the earnings miss.
Why it matters: A lower medical expense ratio shows better cost control. It means the company is more efficient.
Confirms:Medical expense ratio was below 90% in the next quarters.
Disproves:Medical expense ratio remains at or above 93.3%.
